Evaluation of capture and amplicon-based targeted sequencing methods on formalin-fixed tumours
Three capture (Agilent’s SureSelectXT HS, Illumina’s Nextera Rapid Capture Custom, and New England Biolabs’ Next Direct Custom) and one amplicon-based (Qiagen’s Human Breast Cancer Panel) targeted sequencing methods on 6-8 paired blood and FFPE from the Malaysian Breast Cancer Cohort.
- 56 samples
- DAC: EGAC00001001914
- Technology: Illumina MiSeq
Access to controlled data will follow the guidelines provided by the International Cancer Genome Consortium, subject to the Malaysian Personal Data Protection Act.
Access to controlled data will follow the guidelines provided by the International Cancer Genome Consortium. All individual-level sequence data stored on the EGA are controlled and requires the review of the Data Access Committee before access is permitted, to protect patient privacy. All aggregate data and data that cannot be used to re-identify individuals are considered open, and are accessible through the relevant publications. Given that all patients in the cohort are Malaysian, data access is further subject to the Malaysian Personal Data Protection Act and its various prohibitions.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001004965 | Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.